Catalyst Brief

← Calendar

Readoutin 45d

Seagen, a wholly owned subsidiary of Pfizer — disitamab vedotin

Phase 3 primary completion: Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2.

Date
Jan 2027
Type
Readout
Indication
Urothelial Carcinoma

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.